HemoGenyx Pharmaceuticals Plc (HEMO) AI Stock Analysis

• Market Cap: £71.48M
• Dividend Yield: N/A
• Average Volume (3M): 113.41K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.42
• Shares Outstanding: 6,425,429
• 10 Day Avg. Volume: 30,447
• 30 Day Avg. Volume: 113,406
• PEG Ratio: 0.08
• Price to Book (P/B): 14.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: 725.00 p ▲(27.64% Upside)
• Action: Upgraded Date: 01/28/26
• Date: Action: Upgraded 01/28/26

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.

Positive Factors

Specialized Therapeutic Focus

A clear, narrow focus on hematology and oncology and blood/immune disorders supports durable R&D prioritization and scientific expertise. This specialization can improve trial design, regulatory strategy, and partner interest, sustaining pipeline productivity over months.

Platform Technology Opportunity

Owning enabling platform technologies for stem-cell and immune-cell applications creates potential for multiple product derivations, licensing, and collaborations. A reusable platform can generate recurring partners and non-dilutive revenue streams if clinical validation progresses.

Narrowing Operating Cash Burn

Reduced annual cash burn reflects improved cost control and operational discipline versus prior year. If sustained, lower cash consumption extends runway, reduces near-term financing pressure, and increases the chance management can advance programs further before raising capital.

Negative Factors

No Revenue

Absence of any revenue over multiple years signals a pre-revenue R&D stage with no commercial validation yet. This structurally raises execution risk, keeps profitability distant, and makes the company dependent on external financing or partnerships to sustain operations.

Eroding Equity and High Leverage

Significant equity erosion and rising leverage materially weaken the balance sheet, reducing financial flexibility. High debt-to-equity increases likelihood of covenant or refinancing risk and may force dilutive equity raises or limit investment in R&D over the medium term.

Persistent Negative Free Cash Flow

Continued negative free cash flow, even if improving, implies ongoing financing needs. Structural negative FCF undermines sustainability absent new revenue or partnership funding, raising the probability of dilution and constraining long-term program advancement and commercialization timelines.

HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model

Company Description

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

How the Company Makes Money

null

HemoGenyx Pharmaceuticals Plc Financial Statement Overview

Summary

Financials are very weak: no revenue reported across 2020–2024, ongoing sizable losses, and continued cash burn. While 2024 losses and operating/free cash outflow improved versus 2023, equity fell sharply (~0.9m vs ~2.8m) and leverage increased (debt-to-equity ~2.9x), elevating balance-sheet risk and reliance on external funding.

Income Statement

The income statement remains very weak: the company reported zero revenue across 2020–2024, while losses are persistent and sizable. Net loss improved in 2024 versus 2023 (from about -6.7m to -5.6m), but profitability is still deeply negative and the lack of revenue traction limits visibility on a path to sustainable earnings.

Balance Sheet

Balance sheet risk has increased materially. Equity declined sharply to ~0.9m in 2024 (from ~2.8m in 2023), while debt remains meaningful (~2.6m), pushing leverage higher (debt-to-equity ~2.9x in 2024 vs ~1.0x in 2022–2023). Total assets have also trended down since 2021, and returns on equity are strongly negative, reflecting ongoing capital erosion.

Cash Flow

Cash flow is negative but shows some improvement: operating cash burn narrowed in 2024 to ~-4.1m from ~-6.1m in 2023, and free cash flow also improved to ~-4.1m from ~-6.2m. However, the business still consumes significant cash each year and free cash flow remains firmly negative, implying continued dependence on financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-631.38K	-639.28K	-645.68K	-2.60M	-283.65K	-350.72K
EBITDA	-6.94M	-4.71M	-5.73M	-3.42M	-2.39M	-1.96M
Net Income	-7.81M	-5.62M	-6.69M	-3.98M	-5.10M	-2.08M
Balance Sheet
Total Assets	3.10M	4.21M	6.11M	7.09M	8.52M	2.66M
Cash, Cash Equivalents and Short-Term Investments	226.73K	159.26K	1.25M	2.53M	6.84M	1.81M
Total Debt	2.20M	2.62M	2.95M	3.42M	10.15K	1.63M
Total Liabilities	3.65M	3.36M	3.32M	3.85M	352.84K	1.79M
Stockholders Equity	-500.15K	897.51K	2.82M	3.28M	8.19M	890.84K
Cash Flow
Free Cash Flow	-5.58M	-4.13M	-6.22M	-3.34M	-3.45M	-1.97M
Operating Cash Flow	-5.57M	-4.12M	-6.11M	-2.91M	-2.63M	-1.80M
Investing Cash Flow	235.15K	-24.90K	-31.94K	-420.25K	-938.95K	-169.68K
Financing Cash Flow	1.91M	3.08M	4.45M	-110.14K	8.78M	3.21M

HemoGenyx Pharmaceuticals Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HVO	73 Outperform	£54.38M	-137.50	11.97%	2.94%	11.92%	-33.76%
AREC	56 Neutral	£27.18M	-1.64	-197.54%	―	3.31%	21.91%
APTA	52 Neutral	£22.25M	-3.03	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POLB	49 Neutral	£29.97M	-1.92	-53.86%	―	―	―
HEMO	47 Neutral	£71.48M	-0.27	-3931.14%	―	―	―
IMM	46 Neutral	£27.20M	-3.00	3817.30%	―	―	―

HemoGenyx Pharmaceuticals Plc Corporate Events

Hemogenyx Pharmaceuticals Updates Share Capital and Voting Rights Structure

Hemogenyx Pharmaceuticals plc, a clinical-stage biopharmaceutical group listed on the LSE and focused on therapies for blood and autoimmune diseases, operates from London with U.S. subsidiaries in New York City supporting its pipeline of product candidates and platform technologies. The company reported that as of 27 February 2026, its issued share capital comprises 6,425,429 ordinary shares with no treasury shares, establishing the same figure as the total number of voting rights for regulatory disclosure calculations under the FCA’s transparency rules.

This clarification of the company’s voting rights provides investors and other stakeholders with an updated denominator for assessing and reporting their holdings or changes in ownership. The announcement helps ensure compliance with U.K. market disclosure requirements and offers greater transparency regarding Hemogenyx Pharmaceuticals’ capital structure at the current stage of its development.

The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Hemogenyx Raises £118,632 Through Warrant Exercise and Expands Share Capital

Hemogenyx Pharmaceuticals has received notices to exercise warrants over 50,841 new ordinary shares at prices between 180p and 350p, raising £118,632 in fresh capital. The new shares will be admitted to the FCA’s Official List and to trading on the LSE main market, increasing the company’s issued share capital and voting rights base to 6,425,429 shares.

Following admission of the warrant shares, investors are advised to use the new total share count as the reference point for disclosure obligations under the FCA’s transparency rules. The modest equity increase slightly strengthens Hemogenyx’s balance sheet and may support ongoing development of its clinical-stage programmes while marginally diluting existing shareholders’ stakes.

The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML

Hemogenyx Pharmaceuticals has raised £2.5 million from a consortium of private investors via a direct subscription for 333,333 new shares at £7.50 each, alongside three-year warrants exercisable at £9, increasing its issued share capital to 6,374,588 shares. The funding will primarily support the continuation and dose escalation of its Phase I clinical trials for HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia in adults and newly cleared pediatric patients, while the company also cuts costs by outsourcing manufacturing to Made Scientific and continues to advance its CDX and CBR programmes.

The company has received a positive recommendation from the independent Data Safety Monitoring Board to proceed to the next dose level in adults and secured U.S. FDA clearance to begin a pediatric Phase I trial for patients aged 12–18, positioning HG-CT-1 as its lead value driver. Management has focused on reducing burn rate through operational efficiencies, including the external manufacturing transfer, and maintains that progress on its broader pipeline will be reported in due course, with the new capital and admission of the placing shares expected to reinforce its financial footing and market presence.

The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Hemogenyx Raises £2.5m to Advance AML CAR-T Trials and Reduce Costs

Hemogenyx Pharmaceuticals has raised £2.5 million through a direct subscription of 313,333 new shares at £7.50 each from a consortium of private investors, accompanied by three-year warrants exercisable at £9. The funds will primarily support continuation and dose escalation of its Phase I clinical trial of HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia in adults, and the launch of an FDA-cleared Phase I trial in pediatric patients aged 12 to 18.

To conserve cash, the company has outsourced manufacturing of HG-CT-1 to specialist contractor Made Scientific and is finalizing technology transfer to supply both adult and pediatric cohorts, while also progressing its CDX and CBR pipelines where feasible. Following admission of the new shares to the London Stock Exchange’s Main Market, Hemogenyx’s enlarged share capital will total 6,354,588 ordinary shares, positioning the company with additional runway to execute its clinical program and potentially strengthen its standing in the AML treatment landscape.

The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Hemogenyx Confirms Updated Share Capital and Voting Rights

Hemogenyx Pharmaceuticals has confirmed that its total issued share capital as of 30 January 2026 comprises 6,041,255 ordinary shares of 1p each, with none held in treasury, giving the company an equal number of voting rights. This updated share count provides the key denominator for investors to assess and report any holdings or changes in their interests under UK disclosure and transparency rules, ensuring clarity around the company’s capital structure and regulatory compliance for shareholders and market participants.

The most recent analyst rating on (GB:HEMO) stock is a Sell with a £760.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Hemogenyx Sets Early January Date for Admission of New Shares

Hemogenyx Pharmaceuticals has confirmed that the UK Financial Conduct Authority has scheduled an admission hearing for its new ordinary shares on 5 January 2026, with trading in the new shares expected to commence at around 8:00 a.m. on 6 January 2026. The timing update indicates the capital-related process is progressing as planned, with all other terms from the company’s 18 December 2025 announcement remaining unchanged, providing investors and other stakeholders with clarity on the anticipated schedule for the shares’ admission to trading.

Hemogenyx Pharmaceuticals Announces Equity Issuance and Operational Updates

Hemogenyx Pharmaceuticals plc has issued 123,377 new ordinary shares following warrant exercises, restricted stock unit vesting, and obligations under a Deed of Variation. This issuance, raising £190,000 and leading to adjustments in total issued shares and voting rights, reflects the company’s ongoing efforts to fund operational developments and ensure alignment with regulatory requirements, which may strengthen its market positioning and reassure stakeholders.